<DOC>
	<DOC>NCT00739999</DOC>
	<brief_summary>To evaluate pharmacokinetics, pharmacodynamics, safety and tolerability of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia</brief_summary>
	<brief_title>8-Week PK/PD Atorvastatin Study In Children And Adolescents With Heterozygous Familial Hypercholesterolemia</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Genetically confirmed heterozygous familial hypercholesterolemia (HeFH) with LDL greater or equal 4 mmol/L at baseline Evidence or history of clinically significant diseases, homozygous familial hypercholesterolemia (FH)</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>heterozygous familial hypercholesterolemia (HeFH); atorvastatin; pediatric</keyword>
</DOC>